C. Anasetti, D. Amos, P. G. Beatty, F. R. Appelbaum, W. Bensinger et al., Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma, N. Engl. J. Med, vol.320, pp.197-204, 1989.

F. Aversa, A. Tabilio, A. Velardi, I. Cunningham, A. Terenzi et al., Treatment of highrisk acute leukemia with T cell-depleted stem cells from related donors with one fully mismatched HLA haplotype, N. Engl. J. Med, vol.339, pp.1186-1193, 1998.

F. Ciceri, C. Bonini, M. T. Stanghellini, A. Bondanza, C. Traversari et al., Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study, Lancet Oncol, vol.10, pp.489-500, 2009.

L. Ruggeri, M. Capanni, E. Urbani, K. Perruccio, W. D. Shlomchik et al., Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants, Science, vol.295, pp.2097-2100, 2002.

H. G. Ljunggren and K. Kärre, Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism, J. Exp. Med, vol.162, pp.1745-1759, 1985.

B. Glass, L. Uharek, M. Zeis, H. Loeffler, W. Mueller-ruchholtz et al., Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells, Br. J. Haematol, vol.93, pp.412-420, 1996.

L. Luznik, P. V. O'donnell, H. J. Symons, A. R. Chen, M. S. Leffell et al., HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide, Biol. Blood Marrow Transplant, vol.14, pp.641-650, 2008.

A. Bashey and S. R. Solomon, T cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor, Bone Marrow Transplant, vol.49, pp.999-1008, 2014.

H. J. Symons, M. S. Leffell, N. D. Rossiter, M. Zahurak, R. J. Jones et al., Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation, Biol. Blood Marrow Transplant, vol.16, pp.533-542, 2010.

A. Shimoni, M. Labopin, F. Lorentino, M. T. Van-lint, Y. Koc et al., Killer cell immunoglobulinlike receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide, Leukemia, vol.33, pp.230-239, 2019.

A. Russo, G. Oliveira, S. Berglund, R. Greco, V. Gambacorta et al., NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications, Blood, vol.131, pp.247-262, 2018.

P. Armand, H. T. Kim, B. R. Logan, Z. Wang, E. P. Alyea et al., Validation and refinement of the disease risk index for allogeneic stem cell transplantation, Blood, vol.123, pp.3664-3671, 2014.

C. Retiere, C. Willem, N. Legrand, T. Guillaume, K. Gagne et al., NK-cell alloreactivity is associated with acute Gvhd and decreased relapse incidence after T-replete haplo-identical allotransplant with high-dose post-transplant cyclophosphamide, Blood, vol.130, p.3262, 2017.

A. C. Harris, R. Young, S. Devine, W. J. Hogan, F. Ayuk et al., International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute GvHD international consortium, Biol. Blood Marrow Transplant, vol.22, pp.4-10, 2016.

A. H. Filipovich, D. Weisdorf, S. Pavletic, G. Socie, J. R. Wingard et al., , 2005.